FMC’s Tremisia fungicide receives regulatory approval in Ukraine

PHILADELPHIA - FMC Corporation (NYSE:FMC), a $5.2 billion agricultural sciences company with annual revenues of $4.1 billion, announced Monday that its Tremisia fungicide has received regulatory approval in Ukraine, marking the first introduction of the company’s fluindapyr technology in the European, Middle East, and Africa region. According to InvestingPro data, FMC maintains a solid dividend yield of 5.5% and has consistently paid dividends for 20 consecutive years.

The approval covers applications for oilseed rape, sunflower, and wheat across more than 10 million hectares of Ukrainian farmland. Tremisia combines FMC’s proprietary fluindapyr molecule with flutriafol, creating a dual-action fungicide that targets diseases including Alternaria and Sclerotinia in sunflower, and Septoria and rust in wheat.

"This registration fills an important gap in disease management options for Ukrainian growers," said Nataliia Savchenko, FMC Ukraine country leader, according to the company’s press release.

Ukraine ranks among the world’s largest exporters of sunflower, oilseed rape, and wheat, making it a strategically significant market for agricultural products.

The Ukraine registration builds on FMC’s existing commercialization of fluindapyr-based products in several countries including Argentina, Brazil, Mexico, Paraguay, South Korea, and the United States. The company received conditional approval in the Philippines earlier this year.

FMC anticipates launching fluindapyr-based products in additional markets including Bolivia, Chile, Colombia, Honduras, and India, pending regulatory decisions.

FMC Corporation develops crop protection solutions including biologicals, crop nutrition, and digital agriculture technologies.

In other recent news, FMC Corporation has reported a challenging first quarter for 2025, with a 14% decline in sales compared to the previous year. Despite this, the company exceeded earnings expectations with an earnings per share (EPS) of $0.18, surpassing the forecast of $0.09. Revenue for the quarter reached $791 million, exceeding the anticipated $773.77 million. FMC has maintained its full-year EBITDA guidance of $870 million to $950 million, although the company projects a lower second-quarter EBITDA than the consensus estimate.

In a strategic move, FMC Corporation has partnered with Corteva Agriscience to expand the availability of a novel fungicide technology for U.S. corn and soybean growers. This collaboration aims to enhance crop protection tools for farmers, utilizing the active ingredient fluindapyr. Additionally, Wells Fargo has upgraded FMC’s stock rating from Equal Weight to Overweight, citing positive market trends and strategic actions by the company. The firm raised its price target to $50.00, expressing confidence in a near-term bottom for earnings per share.

Goldman Sachs has reaffirmed its Buy rating for FMC Corporation, maintaining a $51.00 price target, following the company’s first-quarter earnings report. Analysts noted the company’s strategic initiatives, including a pipeline of new active ingredients, as potential diversifiers for its portfolio. FMC anticipates significant growth in the second half of 2025, driven by new product volumes and market expansion in Brazil, despite the near-term challenges reflected in the recent stock performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.